Here are the consideration that will go into pricing Genomic medicine as the paradigm shifts.

Greetings, fellow investors! Welcome back to ShareTrekc. I'm Raj, and today, I want to share my thoughts on some extra considerations regarding pricing of genomic medicine. We are experiencing a paradigm shift in medicine from recurring treatment of symptom and disease management to once and done genomic cure. Insurers and payers will have to find ways to evaluate these genomic medicines differently to do justice to patients as well as ensure innovation is rewarded and at the same time avoid over paying. Check out my ideas and let me have your comments.


JOIN THE CHANNEL AS A MEMBER:
Please check out the membership offering and join me in the exciting new chapter for ShareTreck, Thanks for your support so far and looking forward to much more. Use the link below to join or click on the Join button on the bottom left of your screen.

   / @sharetreck  

Please subscribe:    / @sharetreck  

The videos in this channel should not be construed as financial advice. Always make sure to do your own due diligence and research.
Please do not trade or invest based on this video. Information provided in this video is not investment advice and is for entertainment purposes only.
Disease and therapy details are derived from news articles and publications by companies or research organizations. I am not a doctor but am only facilitating dissemination of published information.